Dropped from $8.3+ previous week on weak result Phase 2 study. Results not as bleak as it seem. Solid balance sheet. Waiting for up to $1.3 payment for sold drug. $2.3 cash on hand. Rolontis to be approved (very hugh odds) buy FDA by October 2020. Price targe short term : $5.